A transcriptomic atlas of drug-induced endothelial dysfunction in human endothelial cells

Drug-induced vascular burden is a critical challenge in both pharmaceutical development and clinical setting. In the past two decades, multiple drugs have been withdrawn from the market due to unanticipated adverse vascular complications, such as the increased risk of myocardial infarction and stroke (e.g., sibutramine and valdecoxib), heart valvular disease (e.g., pergolide and dexfenfluramine), and haemorrhagic stroke (e.g., phenylpropanolamine). Furthermore, many cancer drugs, such as anthracyclines, tyrosine kinase inhibitors (TKIs), and proteasome inhibitors, are also well-known to elicit a broad spectrum of vascular dysfunctions [1].
Source: Journal of Molecular and Cellular Cardiology - Category: Cytology Authors: Tags: Letter to the Editor Source Type: research